Serum amyloid A—A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19
Serum amyloid-A (SAA) is associated with inflammatory disorders such as rheumatoid arthritis, Familial Mediterranean Fever, sarcoidosis, and vasculitis. There is accumulating evidence that SAA is a reliable biomarker for these autoinflammatory and rheumatic diseases and may contribute to their patho...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1135695/full |
| _version_ | 1797869601594277888 |
|---|---|
| author | Eman M. Almusalami Anthony Lockett Albert Ferro Albert Ferro John Posner |
| author_facet | Eman M. Almusalami Anthony Lockett Albert Ferro Albert Ferro John Posner |
| author_sort | Eman M. Almusalami |
| collection | DOAJ |
| description | Serum amyloid-A (SAA) is associated with inflammatory disorders such as rheumatoid arthritis, Familial Mediterranean Fever, sarcoidosis, and vasculitis. There is accumulating evidence that SAA is a reliable biomarker for these autoinflammatory and rheumatic diseases and may contribute to their pathophysiology. Hyperinflammatory syndrome associated with COVID-19 is a complex interaction between infection and autoimmunity and elevation of SAA is strongly correlated with severity of the inflammation. In this review we highlight the involvement of SAA in these different inflammatory conditions, consider its potential role and discuss whether it could be a potential target for treatment of the hyperinflammatory state of COVID-19 with many potential advantages and fewer adverse effects. Additional studies linking SAA to the pathophysiology of COVID-19 hyper-inflammation and autoimmunity are needed to establish the causal relationship and the therapeutic potential of inhibitors of SAA activity. |
| first_indexed | 2024-04-10T00:15:12Z |
| format | Article |
| id | doaj.art-28ff21ef8acb4457ba7cb802c8ca0b60 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-10T00:15:12Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-28ff21ef8acb4457ba7cb802c8ca0b602023-03-16T05:11:14ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-03-011010.3389/fmed.2023.11356951135695Serum amyloid A—A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19Eman M. Almusalami0Anthony Lockett1Albert Ferro2Albert Ferro3John Posner4Centre for Pharmaceutical Medicine Research, King’s College London, London, United KingdomCentre for Pharmaceutical Medicine Research, King’s College London, London, United KingdomCentre for Pharmaceutical Medicine Research, King’s College London, London, United KingdomSchool of Cardiovascular and Metabolic Medicine and Sciences, British Heart Foundation Centre for Research Excellence, King’s College London, London, United KingdomCentre for Pharmaceutical Medicine Research, King’s College London, London, United KingdomSerum amyloid-A (SAA) is associated with inflammatory disorders such as rheumatoid arthritis, Familial Mediterranean Fever, sarcoidosis, and vasculitis. There is accumulating evidence that SAA is a reliable biomarker for these autoinflammatory and rheumatic diseases and may contribute to their pathophysiology. Hyperinflammatory syndrome associated with COVID-19 is a complex interaction between infection and autoimmunity and elevation of SAA is strongly correlated with severity of the inflammation. In this review we highlight the involvement of SAA in these different inflammatory conditions, consider its potential role and discuss whether it could be a potential target for treatment of the hyperinflammatory state of COVID-19 with many potential advantages and fewer adverse effects. Additional studies linking SAA to the pathophysiology of COVID-19 hyper-inflammation and autoimmunity are needed to establish the causal relationship and the therapeutic potential of inhibitors of SAA activity.https://www.frontiersin.org/articles/10.3389/fmed.2023.1135695/fullserum amyloid AtargethyperinflammationCOVID-19inflammationcytokines |
| spellingShingle | Eman M. Almusalami Anthony Lockett Albert Ferro Albert Ferro John Posner Serum amyloid A—A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19 Frontiers in Medicine serum amyloid A target hyperinflammation COVID-19 inflammation cytokines |
| title | Serum amyloid A—A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19 |
| title_full | Serum amyloid A—A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19 |
| title_fullStr | Serum amyloid A—A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19 |
| title_full_unstemmed | Serum amyloid A—A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19 |
| title_short | Serum amyloid A—A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19 |
| title_sort | serum amyloid a a potential therapeutic target for hyper inflammatory syndrome associated with covid 19 |
| topic | serum amyloid A target hyperinflammation COVID-19 inflammation cytokines |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1135695/full |
| work_keys_str_mv | AT emanmalmusalami serumamyloidaapotentialtherapeutictargetforhyperinflammatorysyndromeassociatedwithcovid19 AT anthonylockett serumamyloidaapotentialtherapeutictargetforhyperinflammatorysyndromeassociatedwithcovid19 AT albertferro serumamyloidaapotentialtherapeutictargetforhyperinflammatorysyndromeassociatedwithcovid19 AT albertferro serumamyloidaapotentialtherapeutictargetforhyperinflammatorysyndromeassociatedwithcovid19 AT johnposner serumamyloidaapotentialtherapeutictargetforhyperinflammatorysyndromeassociatedwithcovid19 |